Straits Times Index
3,378.29 -15.92 (-0.47%) S&P 500
4,029.05 -41.51 (-1.02%) Dow
33,802.94 -175.14 (-0.52%) Nasdaq
11,433.85 -187.86 (-1.62%) BTC-USD
22,826.11 -1,048.01 (-4.39%) CMC Crypto 200
515.97 -21.91 (-4.07%)
Roche Holding AG (RHHVF)
| Previous close | 315.60 |
| Open | 315.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 312.00 - 316.00 |
| 52-week range | 299.01 - 430.00 |
| Volume | |
| Avg. volume | 6,157 |
| Market cap | 254.895B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 16.23 |
| EPS (TTM) | 19.22 |
| Earnings date | N/A |
| Forward dividend & yield | 9.97 (3.16%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | 423.65 |
- Zacks
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.
- Business Wire
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tec
- Zacks
The Zacks Analyst Blog Highlights UnitedHealth Group, The Coca-Cola, Roche Holding, Lam Research and Valero Energy
UnitedHealth Group, The Coca-Cola, Roche Holding, Lam Research and Valero Energy are part of the Zacks top analyst blog.
